最新ニュース BILL Holdings (NYSE:BILL) 株価情報

BILL Holdings

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

Bill.com Holdings

BILL Holdings Inc

BILL IDENTITY LTD by BILL IDENTITY LTD

Billerud AB

BillionHappiness

Earnings

Earnings Beats

News

GBTG

Global Business Travel Q4 Sales $591.000M Beat $589.170M Estimate

Cannabis

Markets

General

Canopy Growth Has Officially Launched Its Tweed Brand In The German Medical Cannabis Market, Including The Availability Of Four New Tweed Strains Grown In The Eu Through An Agreement With Gro-vida, A Portuguese Medical Cannabis Cultivator

Marcus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCS#NYSE">MCS</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.11 by 72.73 percent. This is a 160 percent increase over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $188.31 million which beat the analyst consensus estimate of $183.00 million by 2.90 percent. This is a 16.58 percent increase over sales of $161.53 million the same period last year.

Earnings Misses

Marcus Q4 2024 GAAP EPS $0.03 Misses $0.11 Estimate, Sales $188.31M Beat $183.00M Estimate

Rosenblatt analyst Steven Frankel maintains Xperi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPER#NYSE">XPER</a>) with a Buy and maintains $15 price target.

Price Target

Analyst Ratings

XPER

Rosenblatt Maintains Buy on Xperi, Maintains $15 Price Target

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.03) by 166.67 percent. This is a 128.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $40.78 million which beat the analyst consensus estimate of $37.37 million by 9.14 percent. This is a 19.13 percent increase over sales of $34.23 million the same period last year.

HRTX

Heron Therapeutics Q4 2024 GAAP EPS $0.02 Beats $(0.03) Estimate, Sales $40.78M Beat $37.37M Estimate

Guidance

TGNA

TEGNA Sees Q1 Revenue Decline Of (-4%) - (-7%)

Baird analyst Jeff Johnson maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Neutral and lowers the price target from $37 to $33.

TNDM

Baird Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $33

TEGNA Sees FY25 Free Cash Flow Of $900M - $1.1B; Capital Expenditure Of $50M - $60M

Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRM#NASDAQ">MIRM</a>) with a Outperform and raises the price target from $50 to $55.

MIRM

Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $55

The study is expected to randomize thirty-six (36) patients in four sites in UAE, which are Cleveland Clinic Abu Dhabi&nbsp;(CCAD), Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD).
 &nbsp;

MDCX

Medicus Pharma Submits Clinical Design (SKNJCT-004) To UAE DOH To Non-Invasively Treat BCC Of The Skin

Rosenblatt analyst Blair Abernethy maintains Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) with a Buy and maintains $660 price target.

SNPS

Rosenblatt Maintains Buy on Synopsys, Maintains $660 Price Target

Baird analyst Joel Beatty maintains Cogent Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) with a Neutral and lowers the price target from $10 to $8.

COGT

Baird Maintains Neutral on Cogent Biosciences, Lowers Price Target to $8

Health Care

Stock Split

VERO

Venus Concept Will Effect A 1-for-11 Reverse Stock Split, Effective At 5:00 P.M. Eastern Standard Time On March 3

Needham analyst David Saxon reiterates ZimVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) with a Buy and maintains $23 price target.

Reiteration

ZIMV

Needham Reiterates Buy on ZimVie, Maintains $23 Price Target

Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) reported quarterly losses of $(0.88) per share which beat the analyst consensus estimate of $(0.99) by 11.11 percent. This is a 19.27 percent increase over losses of $(1.09) per share from the same period last year.

Dyne Therapeutics Q4 2024 GAAP EPS $(0.88) Beats $(0.99) Estimate

Baird analyst Jeff Johnson maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Outperform and raises the price target from $104 to $108.

Baird Maintains Outperform on Alcon, Raises Price Target to $108

Cars.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARS#NYSE">CARS</a>) reported quarterly earnings of $0.49 per share which missed the analyst consensus estimate of $0.56 by 12.5 percent. This is a 2.08 percent increase over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $180.43 million which missed the analyst consensus estimate of $183.90 million by 1.88 percent. This is a 0.46 percent increase over sales of $179.61 million the same period last year.

CARS

CORRECTION: Cars.com Q4 Adj EPS $0.49 Misses $0.56 Estimate, Sales $180.43M Miss $183.90M Estimate

Tegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGNA#NYSE">TGNA</a>) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $1.16 by 4.31 percent. This is a 181.4 percent increase over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $870.53 million which missed the analyst consensus estimate of $870.79 million by 0.03 percent. This is a 19.93 percent increase over sales of $725.85 million the same period last year.

Tegna Q4 Adj $1.21 Beats $1.16 Estimate, Sales $870.53M Miss $870.79M Estimate

Rosenblatt analyst Blair Abernethy maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and maintains $205 price target.

SNOW

Rosenblatt Maintains Buy on Snowflake, Maintains $205 Price Target

Baird analyst Eric Coldwell maintains AdaptHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) with a Outperform and raises the price target from $14 to $16.

AHCO

Baird Maintains Outperform on AdaptHealth, Raises Price Target to $16

Press Releases

BILL to Participate in Upcoming Investor Conference

BILL to Offer $1.0 Billion of Convertible Senior Notes due 2030

BILL Announces Pricing of Upsized Offering of $1.25 Billion of 0% Convertible Senior Notes Due 2030

BILL Announces Closing of Offering of $1.4 Billion of 0% Convertible Senior Notes due 2030, Including Full Exercise of Initial Purchasers' $150.0 Million Option to Purchase Additional Notes

Comments

BILL Holdings

ニュース

最新ニュース BILL Holdings (NYSE:BILL) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル